VectorFlow: Scalable viral vector downstream processing for gene therapy production

点击翻译按钮获取中文摘要

"Successful clinical trials of gene-therapies for a range of disease-indications have led to recent regulatory approvals for commercial use. Commercial-supply of viral vectors is limited by lack of affordable large-scale downstream manufacturing processes,which have several drawbacks in terms of process-related impurities, sample/potency loss and scalability_**,**_ with processing losses as high as 90%. Hence, improved scalable methods that guarantee viral vector yield and safety without compromising infectivity/functionality are urgently needed for high-efficiency gene-therapy manufacturing.VectorFlow brings innovative chemical-free viral-vector extraction/pre-filtration to gene-therapy production. This will overcome a key downstream bioprocessing bottleneck and play a pivotal role in increasing the yield and quality of viable viral-vectors in a scalable, low-cost manner, helping to increase the UK's commercial capacity to manufacture viral-vectors for the development of gene therapies to treat human disease. As a platform downstream bioprocessing technology, the VectorFlow platform can also be expanded to other advanced therapy and biomanufacturing applications to maximise commercial impact within the health and life sciences sector."